Focused On-demand Library for tRNA-splicing endonuclease subunit Sen15

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We use our state-of-the-art dedicated workflow for designing focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q8WW01

UPID:

SEN15_HUMAN

Alternative names:

SEN15 homolog; tRNA-intron endonuclease Sen15

Alternative UPACC:

Q8WW01; B4DKP0; Q9BZQ5

Background:

The tRNA-splicing endonuclease subunit Sen15, also known as SEN15 homolog, plays a crucial role in the maturation of tRNA molecules. It is a non-catalytic component of the tRNA-splicing endonuclease complex, essential for the cleavage of pre-tRNA at the 5' and 3' splice sites. This process releases the intron and produces two tRNA half-molecules, a fundamental step for proper tRNA function and, consequently, protein synthesis.

Therapeutic significance:

Sen15's involvement in Pontocerebellar hypoplasia 2F, a neurodevelopmental disorder, highlights its potential as a therapeutic target. Understanding the role of tRNA-splicing endonuclease subunit Sen15 could open doors to potential therapeutic strategies, offering hope for treatments that could mitigate or possibly reverse the progression of this debilitating condition.